Individuals who are moderately or severely immunocompromised, such as those undergoing chemotherapy or with rheumatoid arthritis, can now receive additional doses of the
2024-2025 COVID-19 vaccine after completing the standard recommended doses. Based on recommendations from the Centers for Disease Control and Prevention (CDC), the decision to receive extra doses should be made following a discussion with their healthcare provider in a shared clinical decision-making process to better assess personal risks and benefits. The additional doses are recommended to further enhance protection for this population against serious COVID-19 complications. Read more at: https://www.cdc.gov/media/releases/2024/s1023-covid-19-vaccine.html; https://www.cdc.gov/covid/vaccines/immunocompromised-people.html
Comments